Talk:Pegvisomant
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pegvisomant.
|
Wiki Education Foundation-supported course assignment
[edit]This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): KFunk740.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 06:19, 17 January 2022 (UTC)
In the News
[edit]This drug is the subject of a current event: http://www.nytimes.com/2011/02/17/science/17longevity.html —Preceding unsigned comment added by 148.87.67.132 (talk) 01:55, 17 February 2011 (UTC)
Origin
[edit]John Kopchick discovered Pegvisomant in 1987, and it was approved by the FDA in 2003. This information should be included in this article. Here's an interesting source for that: http://www.ohio.edu/research/communications/royaltymonetization.cfm
--Dulcimerist (talk) 21:05, 6 May 2012 (UTC)
Side Effects
[edit]Citations relatively outdated, and incomplete/inaccurate. See more extensive data in Acrostudy [1] KFunk740 (talk) 15:36, 19 October 2016 (UTC)
References
Other Uses
[edit]Pegvisomant can potentially inhibit growth of some types of tumors.,[1][2] KFunk740 (talk) 15:46, 19 October 2016 (UTC)
References
General Comments
[edit]Overall structure is OK enough, but can be expanded quite a bit. I agree with Dulcimerist, that article needs a section on the drug discovery and linked to John Kopchick's wiki article, along with revenue data for Ohio University. Intro section needs to be clarified. It appears imbalanced toward lack of efficacy, but more recent data is more convincing that it does improve health and quality of life. Sources stated aren't reliable enough. (hopefully this gets a few more points on assignment). KFunk740 (talk) 00:14, 28 October 2016 (UTC)
- Start-Class pharmacology articles
- Mid-importance pharmacology articles
- WikiProject Pharmacology articles
- Start-Class Molecular Biology articles
- Unknown-importance Molecular Biology articles
- Start-Class MCB articles
- Low-importance MCB articles
- WikiProject Molecular and Cellular Biology articles
- All WikiProject Molecular Biology pages
- Start-Class medicine articles
- Mid-importance medicine articles
- All WikiProject Medicine pages